You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨康諾亞-B(2162.HK)漲超9% TSLP抗體與石藥達成合作 加速臨牀開發
格隆匯 11-24 10:35
格隆匯11月24日丨康諾亞-B(2162.HK)快速拉昇漲超9%,報46.2港元,總市值130億港元。公司22日宣佈與石藥集團就TSLP抗體CM326 在中重度哮喘和慢性阻塞性肺病(COPD)等呼吸系統疾病獨家授權開發及商業化正式簽訂協議。中金為公司能夠藉助石藥在呼吸系統疾病上的臨牀資源和商業化能力,加速產品在這些適應症上的開發。同時公司將保留CM326 在其它適應症上的所有權益,CM326 治療中重度特應性皮炎的適應症也已獲批臨牀。維持公司跑贏行業評級和75港元目標價。另外,核心產品IL-4Rα抗體CM310 順利推進中,公司計劃於2021年底公佈Ph2b結果。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account